May 25, 2022
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss the role of NAFLD patient advocacy in the Fatty Liver community. This conversation centers around the importance of taking action locally and enhancing communication across stakeholder groups if we are to keep increasing momentum over time.
Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss value of NAFLD patient advocacy in the Fatty Liver community. This conversation focuses on whether there is an actual integrated community along with key areas to build successes.
Achim Kautz and Andrew Scott discuss some of their successes in patient advocacy, while Louise Campbell raises a question about which patients should be the focus of advocates’ activities.
Achim Kautz, Andrew Scott and Jörn Schattenberg share their experiences in talking with public officials about Fatty Liver disease and liver health.
Leading NAFLD patient advocates Achim Kautz and Andrew Scott discuss how their personal backgrounds (that are quite different) brought them to the place where they work in serving the Fatty Liver community.
Patient advocates Andrew Scott from the Global Liver Institute and Achim Kautz from Germany share their backgrounds, perspective, goals, and strategies with the Surfers.
